Stocks · News reference
LeMaitre Vascular Sees Q3 GAAP EPS $0.66-$0.71 vs $0.73 Est; Sees Sales $66.300M-$68.300M vs $69.246M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.66-$0.71 vs $0.73 analyst estimate. sees sales of $66.300 million-$68.300 million vs $69.246 million analyst estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LeMaitre Vascular shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 GAAP EPS and FY2026 sales guidance.
8-K filing — LEMAITRE VASCULAR INC (LMAT)
Filed: 2026-08-04 AccNo: 0001193125-26-332982 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
LeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.